Cargando…

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria

BACKGROUND: Immunotherapy plays an important role in advanced non‐small cell lung cancer (NSCLC). However, radiological evaluation is challenging due to the potential inflammatory effects of immunotherapy, which can lead to atypical response patterns. Identifying these atypical responses is critical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liang, Hongge, Xu, Yan, Chen, Minjiang, Zhong, Wei, Wang, Mengzhao, Zhao, Jing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113040/ https://www.ncbi.nlm.nih.gov/pubmed/32129934 http://dx.doi.org/10.1111/1759-7714.13367

Ejemplares similares

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
por: Xie, Peiyi, et al.
Publicado: (2021)

iRECIST and atypical patterns of response to immuno-oncology drugs
por: Ramon-Patino, Jorge Luis, et al.
Publicado: (2022)

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
por: Zheng, Bingjie, et al.
Publicado: (2021)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?
por: Lee, Dong Ho, et al.
Publicado: (2021)

Evolution of Radiological Treatment Response Assessments for Cancer Immunotherapy: From iRECIST to Radiomics and Artificial Intelligence
por: Kim, Nari, et al.
Publicado: (2022)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Is response evaluation criteria in solid tumors (RECIST) effective in patient selection for radical resection after neoadjuvant immunotherapy with advanced NSCLC?
por: Xu, Yuan, et al.
Publicado: (2023)

Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?
por: Gupta, Manoj, et al.
Publicado: (2022)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
por: Song, Peng, et al.
Publicado: (2019)

iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison
por: Schomburg, Laura, et al.
Publicado: (2022)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria
por: Reginelli, Alfonso, et al.
Publicado: (2023)

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
por: Beaver, Julia A., et al.
Publicado: (2018)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
por: Luo, Yanji, et al.
Publicado: (2017)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Feasibility of continuing crizotinib therapy after RECIST-PD in advanced non-small cell lung cancer patients with ALK/ROS-1 mutations
por: Liu, Jun, et al.
Publicado: (2018)

Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement
por: Ghobrial, Fady Emil Ibrahim, et al.
Publicado: (2017)

Intra- and inter-observer variability in measurement of target lesions: implication on response evaluation according to RECIST 1.1
por: Muenzel, Daniela, et al.
Publicado: (2012)

WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
por: Ades, Felipe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j6ndflflebbgdvq6r6bgkafomb